| Name | Title | Contact Details |
|---|
PharmaNet is an international drug development company employing about 1,500 professionals worldwide.
ABC Medical Management is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Memorial Hospital at Gulfport is a not-for-profit medical complex in Gulfport, Mississippi, jointly owned by the City of Gulfport and Harrison County. Memorial is one of the most comprehensive healthcare systems in the state, licensed for 303 beds, including a state-designated Level II Trauma Center, two outpatient surgery centers, satellite outpatient diagnostic and rehabilitation centers and more than 95 Memorial Physician Clinics. Memorial offers several of the region`s most comprehensive clinical programs, such as emergency medicine; women and children services; orthopedic services; cardiovascular services; neurosciences and oncology. Additionally, Memorial provides medical specialties unique to the coast which include a Level III Neonatal ICU and Mississippi`s first nationally certified Primary Stroke Center. Memorial offers 3D imaging and advanced surgical techniques, including the robotic assisted Specialty Surgery System. Memorial is accredited by The Joint Commission, the Commission on Cancer, the College of American Pathologists and the American College of Radiology.
NEOMED is a Woodstock, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.